Altair Therapeutics Names New CEO

San Diego-based Altair Therapeutics, which is developing treatments for respiratory diseases, said Thursday that it has named Joel Martin, Ph.D., as its President and CEO. Marin was most recently a venture capitalists at Forward Ventures--one of the principal backers of Altair--where he was in charge of investments in Cellective Therapeutics, Hypnion, Predeix Pharmaceuticals, Novostent, and others. Martin also served at Isis Pharmaceuticals, Argonaut Technologies, and Quantum Dot Corp. Altair said that current CEO Paul Brennan will continue on at the firm, working in a business development capacity.